PLoS ONE (Jan 2022)

Prevalence and determinants of oral and cervicogenital HPV infection: Baseline analysis of the Michigan HPV and Oropharyngeal Cancer (MHOC) cohort study.

  • Andrew F Brouwer,
  • Lora P Campredon,
  • Heather M Walline,
  • Brittany M Marinelli,
  • Christine M Goudsmit,
  • Trey B Thomas,
  • Rachel L Delinger,
  • Yan Kwan Lau,
  • Emily C Andrus,
  • Monica L Yost,
  • Jodi K McCloskey,
  • Taylor S Sullivan,
  • Alex S Mortensen,
  • Suiyuan Huang,
  • Keith Murphy,
  • Bonnie Cheng,
  • Kayla Stanek,
  • Thankam Nair,
  • Thomas E Carey,
  • Rafael Meza,
  • Marisa C Eisenberg

DOI
https://doi.org/10.1371/journal.pone.0268104
Journal volume & issue
Vol. 17, no. 5
p. e0268104

Abstract

Read online

We determined baseline oral and cervicogenital human papillomavirus (HPV) prevalence and determinants of infection in the Michigan HPV and Oropharyngeal Cancer (MHOC) study. We enrolled 394 college-age and older participants of both sexes in Ann Arbor, Michigan and the surrounding area. All participants provided an oral sample at baseline, and 130 females provided a cervicogenital sample. Samples were tested for 18 HPV genotypes using polymerase chain reaction (PCR) MassArray. Participants filled out sociodemographic and behavioral questionnaires. Prevalence ratios for HPV oral or cervicogenital prevalence by predictor variables were estimated in univariable log-binomial models. Analysis was conducted 2018-20. In the full cohort, baseline oral HPV prevalence was 10.0% for any detected genotype (among the 338 valid oral tests at baseline) and 6.5% for high-risk types, and cervicogenital prevalence was 20.0% and 10.8%, respectively (among the 130 first valid cervicogenital tests). Oral HPV prevalence did not vary by sex, with 10.5% of women and 9.0% of men having an infection. We found a high prevalence of oral and cervicogenital HPV infection in college-age participants reporting no lifetime sexual partners. Reporting a single recent partner was associated with a lower oral HPV prevalence (PR 0.39, 95% CI: 0.16, 0.96) than reporting no recent (but at least one ever) partner. No similar protective effect was seen for cervicogenital HPV. Both oral and cervicogenital prevalence increased with the number of recent partners for most sexual behaviors. We observed an ecological fallacy masking the direction of impact of vaccination on HPV prevalence in the full cohort compared to the college-aged and the age 23+ populations considered separately. Substance use was not significantly associated with oral or cervicogenital HPV infection. Many studies report substantially higher oral HPV infection prevalence in men than in women. That difference may not be uniform across populations in the US.